Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenACWY-CRM in Infants
NCT01000311Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Nov 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Subjects With hSBA Titer >= 1:8 Against Serogroup A, C, W and Y. Started Nov 2009; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01000311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000311.